ArticlemAbs
Antibodies to watch in 2010.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Review
- Predicting Human Bioavailability of Subcutaneously Administered Fusion Proteins and Monoclonal Antibodies Using Human Intravenous Clearance or Antibody Isoelectric Point.The AAPS journal · 2023Article
- Transmembrane stem cell factor protein therapeutics enhance revascularization in ischemia without mast cell activation.Nature communications · 2022Article
- Production, characterization, and epitope mapping of monoclonal antibodies of ribosomal protein S3 (rpS3).Animal cells and systems · 2021Article
- Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective.Molecules (Basel, Switzerland) · 2020Review
- Antibodies to watch in 2016.mAbs · 2016Article
- The immunogenicity of antibody aggregates in a novel transgenic mouse model.Pharmaceutical research · 2015Article
- Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics.Critical reviews in biotechnology · 2015Review
- Antibodies to watch in 2015.mAbs · 2015Review
- Application of AMOR in craniofacial rabbit bone bioengineering.BioMed research international · 2015Article
- Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications.Protein engineering, design & selection : PEDS · 2014Article
- Antibodies to watch in 2014.mAbs · 2014Article
- With or without sugar? (A)glycosylation of therapeutic antibodies.Molecular biotechnology · 2013Review
- Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display.Methods (San Diego, Calif.) · 2013Review
- Expression of recombinant antibodies.Frontiers in immunology · 2013Article
- Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.The Journal of biological chemistry · 2012Article
- Using in-vivo fluorescence imaging in personalized cancer diagnostics and therapy, an image and treat paradigm.Technology in cancer research & treatment · 2011Review
- A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.Journal of virology · 2011Article
- Cancer radioimmunotherapy.Immunotherapy · 2011Review
- Advances in the assessment and control of the effector functions of therapeutic antibodies.Nature reviews. Drug discovery · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies (mAbs) are a burgeoning class of therapeutics, with more than 25 approved in countries worldwide. Novel molecules are entering clinical study at a rate of nearly 40 per year, and the commercial pipeline includes approximately 240 mAb therapeutics in clinical studies that have not yet progressed to regulatory approval or been approved. Of particular interest are the 26 mAbs that are currently at Phase 3, when safety and efficacy data critical to approval is established. Phase 3 study lengths are typically two to four years, so results for some studies might be announced in 2010, but data from others might not be presented until 2014. This overview of the 26 candidates provides a brief description of the background and the on-going Phase 3 studies of each mAb. Additional mAbs that have progressed to regulatory review or been approved may also be in Phase 3 studies, but these, as well as Fc fusion proteins, have been excluded. Due to the large body of primary literature about the 26 candidates, only selected references are given, with a focus on recent publications and articles that were relevant to Phase 3 studies. Current as of October 2009, the results presented here will serve as a baseline against which future progress can be measured.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.